ImmunityBio ( (IBRX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ImmunityBio Inc. has seen its stock price rise following the announcement of a collaboration and supply agreement with BeiGene for a Phase 3 clinical trial. This trial will explore the combination of BeiGene’s tislelizumab and ImmunityBio’s Anktiva to improve survival in patients with advanced or metastatic NSCLC resistant to immune CPI therapy. The trial’s potential to address unmet medical needs in oncology has attracted attention to ImmunityBio’s stock. Additionally, the acceptance of Anktiva’s Marketing Authorization Application (MAA) for review by the European Medicines Agency (EMA) further boosts confidence in the company’s future, influencing analyst perceptions and stock price targets positively.
More about ImmunityBio
YTD Price Performance: 19.84%
Average Trading Volume: 6,013,453
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.25B
For further insights into IBRX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.